Indraprastha Medical Corporation Limited (NSE:INDRAMEDCO)
India · Delayed Price · Currency is INR 365.35
+5.55 (1.54%)
Jul 31, 2026, 3:29 PM IST
NSE:INDRAMEDCO Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 14,825 | 13,564 | 12,447 | 10,987 | 8,882 | |
Revenue Growth | 9.30% | 8.97% | 13.29% | 23.70% | 44.80% |
Cost of Revenue | 9,333 | 5,278 | 5,040 | 4,630 | 4,059 |
Gross Profit | 5,492 | 8,286 | 7,407 | 6,357 | 4,823 |
Selling, General & Admin | - | 876.5 | 1,066 | 894.6 | 552.1 |
Other Operating Expenses | 2,823 | 4,961 | 4,396 | 3,947 | 3,070 |
Operating Expenses | 3,259 | 6,281 | 5,863 | 5,234 | 3,972 |
Operating Income | 2,233 | 2,005 | 1,545 | 1,123 | 851.3 |
Interest Expense | -60.2 | -30.3 | -10.6 | -4.6 | -6.1 |
Interest & Investment Income | - | 226.5 | 168.9 | 100.3 | 31.2 |
Other Non Operating Income (Expenses) | 287.5 | -32.4 | -30 | -38.2 | -28 |
EBT Excluding Unusual Items | 2,460 | 2,168 | 1,673 | 1,181 | 848.4 |
Gain (Loss) on Sale of Assets | - | -5.2 | -11.7 | -8.7 | -57.7 |
Pretax Income | 2,460 | 2,163 | 1,661 | 1,172 | 790.7 |
Income Tax Expense | 624 | 553.3 | 421.5 | 310.3 | 204.5 |
Net Income | 1,836 | 1,610 | 1,240 | 861.5 | 586.2 |
Net Income to Common | 1,836 | 1,610 | 1,240 | 861.5 | 586.2 |
Net Income Growth | 14.06% | 29.87% | 43.89% | 46.96% | 2415.88% |
Shares Outstanding (Basic) | 92 | 92 | 92 | 92 | 92 |
Shares Outstanding (Diluted) | 92 | 92 | 92 | 92 | 92 |
Shares Change | -0.00% | - | - | - | - |
EPS (Basic) | 20.03 | 17.56 | 13.52 | 9.40 | 6.39 |
EPS (Diluted) | 20.03 | 17.56 | 13.52 | 9.40 | 6.39 |
EPS Growth | 14.07% | 29.88% | 43.87% | 47.07% | 2456.00% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 1,078 | 1,204 | 1,308 | 998.9 | 648.2 |
Free Cash Flow Per Share | 11.76 | 13.14 | 14.26 | 10.90 | 7.07 |
Dividend Per Share | 4.000 | 4.500 | 4.500 | 3.000 | 2.500 |
Dividend Growth | -11.11% | 0% | 50.00% | 20.00% | - |
Gross Margin | 37.04% | 61.09% | 59.51% | 57.86% | 54.30% |
Operating Margin | 15.06% | 14.78% | 12.41% | 10.22% | 9.59% |
Profit Margin | 12.39% | 11.87% | 9.96% | 7.84% | 6.60% |
Free Cash Flow Margin | 7.27% | 8.88% | 10.51% | 9.09% | 7.30% |
EBITDA | 2,669 | 2,405 | 1,907 | 1,477 | 1,160 |
EBITDA Margin | 18.00% | 17.73% | 15.32% | 13.44% | 13.06% |
D&A For EBITDA | 436.3 | 400.7 | 362.8 | 354 | 308.3 |
EBIT | 2,233 | 2,005 | 1,545 | 1,123 | 851.3 |
EBIT Margin | 15.06% | 14.78% | 12.41% | 10.22% | 9.59% |
Effective Tax Rate | 25.36% | 25.58% | 25.37% | 26.48% | 25.86% |
Revenue as Reported | 15,113 | 13,790 | 12,616 | 11,087 | 8,913 |